ALX Oncology and Sanofi to Evaluate Evorpacept + SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
“We are thrilled to enter this collaboration with Sanofi that has the potential to advance a new combination therapy for patients with relapsed multiple myeloma who would benefit from novel effective treatment options,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. “The combination of blocking both CD47 and CD38 has shown synergistic anti-tumor activity in preclinical studies, and this combination may re-sensitize tumors to anti-CD38 treatment or overcome anti-CD38 resistance. This collaboration expands our robust clinical development pipeline with evorpacept, which we intend to establish as a new and best-in-class foundational immunotherapy in both hematologic and solid tumors.”
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a